VYALEV (Foscarbidopa; Foslevodopa) Patent Expiration, LOE Window & CMS Spending

VYALEV (Foscarbidopa; Foslevodopa) by AbbVie: FDA Orange Book core substance LOE 2035-10-21 (last listed 2040-06-10), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $2,293 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN216962 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-10-21
Last Listed Patent or Exclusivity Date2040-06-10
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,293 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.